Une thrombose veineuse profonde révélant une agénésie de la veine cave inférieure

Pichon, Maud; Hij, A.; Wifaq, Bouchra; Abderrahmane, Malika; Jarrari, M. El; Menn, Anne-Marie

doi:10.1016/j.jdmv.2018.11.005

Cited by 6 publications

(2 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…En un estudio realizado en el 2005, se analizaron 116 pacientes menores de 50 años sin otros factores de riesgo para trombosis iliaca y se determinó que en 16% existía alguna malformación de la (3) vena cava inferior asociada y en todos los casos existía trombosis distal a la malformación . La trombosis de la esta vena puede ser tratada exitosamente con trombólisis como se ha demostrado en (4) algunos casos .…”

Section: Introductionunclassified

Extensive venous thrombosis in a patient with inferior vena cava agenesis

Franco

2022

Rev. virtual Soc. Parag. Med. Int

View full text Add to dashboard Cite

show abstract

Section: Introductionunclassified

Extensive venous thrombosis in a patient with inferior vena cava agenesis

Franco

2022

Rev. virtual Soc. Parag. Med. Int

View full text Add to dashboard Cite

show abstract

“…На сьогодні світовий досвід лікування венозних тромбозів з вродженими аномаліями розвитку нижньої порожнистої вени базується на повідомленнях окремих авторів [21,22]. Через це відсутні сучасні ре-комендації та консенсуси з цього питання.…”

unclassified

Treatment of Bilateral Venous Thrombosis in a Patient with Aplasia of the Inferior Vena Cava

Khrebtiy

Tsyhalko²,

Melnychuk³

2022

ujcvs

View full text Add to dashboard Cite

The aim. In the treatment of venous thromboembolism, a special place is occupied by patients with congenital anomalies of the development of the inferior vena cava (IVC). To date, only single cases of treatment of this pathology have been described in the literature. Studying the experience of treating patients with congenital anomalies of the IVC will allow to improve the results of treatment of this category of patients. Materials and methods. Patient B., a 36-year-old man, applied to the vascular surgery clinic of the Vinnytsia Regional Pyrohov Clinical Hospital in July 2010 with complaints of pain, swelling, cyanosis of both lower extremities, which bothered the patient for about 10 days. The patient had no history of venous insufficiency of both lower extremities. An objective examination revealed cyanosis and swelling of both lower extremities. A duplex scan of both lower extremities revealed hyperechoic iliofemoral thrombosis of both lower extremities. Aplasia of the IVC was diagnosed. The common iliac veins on both sides formed a collateral that flowed into the left renal vein. The infrarenal segment of the inferior vena cava was absent. Thrombosis spread from tibial to popliteal, femoral, iliac veins with venous collateral thrombosis up to the level of the left renal vein. The patient received enoxaparin at a dose of 1 mg per kg of body weight twice a day for 7 days with subsequent transition to warfarin under the control of international normalized ratio. Warfarin was prescribed from a starting dose of 5 mg with subsequent control of international normalized ratio in the range of 2.0-3.0. Venotonic and anti-inflammatory drugs were also prescribed. In combination with drug therapy, class 2 elastic compression stockings were recommended. After the treatment, the patient’s condition improved, swelling and cyanosis of both lower extremities regressed. Repeated duplex scanning at the discharge of the patient from the hospital after 7 days showed signs of initial recanalization of the affected venous segments and no progression of thrombosis. Conclusions. Thus, this clinical case showed that the use of anticoagulant therapy allows to obtain satisfactory results in the treatment of patients with congenital anomalies of the development of IVC, to avoid the development of pulmonary embolism and other life-threatening conditions. At the same time, such patients need regular follow-up examinations in order to adjust the treatment and prevent the development of IVC syndrome.

show abstract

Direct Oral Anticoagulants for Inferior Vena Cava Agenesis

Iarossi,

Hermans

2023

Clin Appl Thromb Hemost

View full text Add to dashboard Cite

Deep vein thrombosis (DVT) is common in the general population, with an annual incidence of 1 to 2 per 1000 people. Inferior vena cava agenesis (IVCA) increased the risk of developing DVT and is found in approximately 5% of young adults (20-40-year-olds) diagnosed with unprovoked proximal DVT. IVCA can be caused by a defective embryological process, or be a result of intrauterine or perinatal thrombosis. Its estimated incidence in the general population ranges from 0.0005% to 1%, usually involving a partial absence of one of the four segments of the inferior vena cava (IVC). The management during the extended phase of patients with DVT associated with IVCA is not yet harmonized, as it is poorly described in the literature. Patients with IVCA are considered to be at high risk of DVT occurrence, prompting physicians to continue extended anticoagulation, often using vitamin K antagonists. In this retrospective study, we present a cohort of 11 patients diagnosed with IVCA following a DVT, who subsequently received extended treatment with a direct oral anticoagulants. These findings offer reassuring insights into the extended utilization of direct oral anticoagulants, demonstrating both antithrombotic efficacy and a favorable safety profile.

show abstract

Une thrombose veineuse profonde révélant une agénésie de la veine cave inférieure

Cited by 6 publications

References 76 publications

Extensive venous thrombosis in a patient with inferior vena cava agenesis

Extensive venous thrombosis in a patient with inferior vena cava agenesis

Treatment of Bilateral Venous Thrombosis in a Patient with Aplasia of the Inferior Vena Cava

Direct Oral Anticoagulants for Inferior Vena Cava Agenesis

Contact Info

Product

Resources

About